Vivani Medical, Inc. (VANI) on Monday reported a loss of $6.1 million in its fourth quarter. On a per-share basis, the Alameda, California-based company said it had a loss of 11 cents. For the year, ...

Vivani anticipates the announcement of key milestones associated with the ongoing first-in-human LIBERATE-1 trial, including last subject ...

Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in ...

March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, ...

Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...

March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani” or the "Company”), a clinical-stage ...

ALAMEDA, Calif. - Vivani Medical, Inc. (NASDAQ: VANI), a biopharmaceutical company with a market capitalization of $65.16 million, announced promising preclinical results for its NPM-139, a ...

Vivani Medical, Inc. (NASDAQ: VANI) shares dropped in price Wednesday, as the Alameda, Calif.-based clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, ...

March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, ...

Single dose of Vivani’s NPM-139 semaglutide implant led to nearly 20% weight loss in rats, suggesting once- or twice-yearly dosing. NPM-139 showed steady semaglutide release with potential for ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...